Ongoing treatment(s)-Biological therapy-Targeted Therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy-Targeted Therapy Posts on Medivizor

Evaluating blood vessel-related side effects of long-term use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Evaluating blood vessel-related side effects of long-term use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Posted by on Oct 3, 2021 in Leukemia | 0 comments

In a nutshell This study examined the association between long-term use of three different tyrosine kinase inhibitors (TKIs) and the occurrence of vascular (blood vessel) adverse events (side effects; VAEs) in patients with chronic myeloid leukemia (CML). The data showed a possibly higher risk of developing VAEs when patients with CML were...

Read More

Long-term treatment-free remission for patients with chronic phase chronic myeloid leukemia after second line nilotinib treatment 

Long-term treatment-free remission for patients with chronic phase chronic myeloid leukemia after second line nilotinib treatment 

Posted by on Jun 13, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate long-term treatment-free remission (TFR) for patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were treated with nilotinib (Tasigna) as a second-line treatment.   This study concluded that TFR is safe and durable in these patients.   Some background The...

Read More

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Is long-term treatment-free remission possible after frontline nilotinib treatment in patients with chronic phase chronic myeloid leukemia?

Posted by on Apr 21, 2021 in Leukemia | 0 comments

In a nutshell This study provided an updated 5-year assessment of treatment-free remission (TFR) after frontline nilotinib (Tasigna) treatment in patients with chronic-phase (CP) chronic myeloid leukemia (CML). The data showed sustained, long-term high TFR rates with effectiveness and safety in these patients. Some background Long-term treatments...

Read More

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Evaluating the impact of novel agents on allogeneic stem cell transplant outcomes for chronic lymphocytic leukemia 

Posted by on Oct 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if allogeneic stem cell transplantation (allo-SCT) was a safe and effective option for the treatment of patients with chronic lymphocytic leukemia (CLL) after treatment with novel agents (NA).  This study concluded that this treatment option was safe and effective for patients with...

Read More

Atrial fibrillation as a side effect of ibrutinib treatment in patients with chronic lymphocytic leukemia

Atrial fibrillation as a side effect of ibrutinib treatment in patients with chronic lymphocytic leukemia

Posted by on Jun 23, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the occurrence of atrial fibrillation (abnormal heart rhythm) in patients with chronic lymphocytic leukemia who are treated with ibrutinib.   This study concluded that atrial fibrillation does not require ibrutinib treatment to be stopped but is associated with worse outcomes for...

Read More

Differentiation syndrome in patients of IDH-mutated acute myeloid leukemia treated with ivosidenib and enasidenib

Differentiation syndrome in patients of IDH-mutated acute myeloid leukemia treated with ivosidenib and enasidenib

Posted by on Jun 7, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the occurrence of differentiation syndrome (DS) in patients with IDH-mutated acute myeloid leukemia (AML) under ivosidenib (Tibsovo) and enasidenib (Idhifa) therapy. The authors found that DS is a common and adverse condition in such patients. Some background Mutations or changes in the isocitrate dehydrogenase (IDH)...

Read More

Kidney function in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors

Kidney function in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors

Posted by on May 17, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate kidney function in patients with chronic-phase (CP) chronic myeloid leukemia (CML) before and after tyrosine kinase inhibitor (TKI) treatment.  This study concluded that long-term TKI treatment leads to kidney side effects in these patients that may be irreversible after stopping...

Read More

Second-line tyrosine kinase treatment in patients with chronic myeloid leukemia who have failed first-line treatment

Posted by on Apr 3, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate second-line tyrosine kinase inhibitor (TKI) treatment in patients with chronic-phase chronic myeloid leukemia (CP-CML) who had failed first-line TKI treatment.  This study concluded that these patients have good outcomes with second-line TKI treatment.   Some background Tyrosine kinase...

Read More

Searching for patients with relapsed or unresponsive chronic lymphocytic leukemia to test an immune cell-stimulating treatment

Posted by on Dec 19, 2019 in Leukemia | 0 comments

In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells.  The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH,...

Read More